House dust mite induced allergic asthma/rhinitis
Conditions
Interventions
treatment:immunotherapy
control:symptomatic drug
Sponsors
Nanjing Children's hospital
Eligibility
Sex/Gender
All
Age
2 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1. Age 5-14year (No gender preference); 2. Mild to moderate allergic rhinitis (or with allergic athma)patient, PEF>=70%of predicted value; 3. Positive Skin Prick Test (SPT) response, wheal SI index >=0.5(++); 4. Patients who is fail to meet one of the above criteria is excluded from the trial.
Exclusion criteria
Exclusion criteria: 1. EFV1 <=70% of predicted value; 2. Asthma onset during the screen period, accept the treatment of inhaled or systematic corticosteroids, the daily dose over 800ug of Beclomethasone, over 15 days, or take oral prednisone frequently; 3. Current upper respiratory tract infection, severe atopic dermatitis, acute sinusitis, acute ear or other relevant infectious diseases or under the treatment; 4. Previous treatment by immunotherapy with house dust mite allergen extracts within the previous 5 years; 5. With underlying diseases such as heart disease, pulmonary disease, liver disease, kidney disease and serum diease; 6. Patient is under treatment with beta-blocker; 7. Patient is immune deficiency/low immune function,or under the treatment of immunotherapy; 8. Patient is allergic, hypersensitive or intolerance to first-aid medicine; 9. A mental condition rendering the patient unable to understand the nature, scope and possible consequences of the trial, and/or evidence of an uncooperative attitude; 10. Unlikely to be able to complete the trial, for any reason, or likely to move, or travel for extended periods of time during the trial period; 11. Patients who meet one of above exclusive criteria will be excluded from the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Specific IgG4;Specific IgE blocking factor; | — |
Countries
China
Contacts
Public ContactDeyu Zhao
Outcome results
None listed